Event overview and recent stock move

Recent trading in Hinge Health (HNGE) has caught investor attention after the stock declined 4.0% in the latest session, while remaining higher over the past week, month, and past 3 months.

The 1 day share price decline sits against a stronger backdrop, with the 30 day share price return of 28.73% and 1 year total shareholder return of 44.97% pointing to momentum that has been building rather than fading.

If Hinge Health’s recent move has you interested in other AI driven healthcare opportunities, it could be a good moment to scan the market using our 39 healthcare AI stocks.

With the stock up strongly over the past year and trading at US$58.48, while still sitting below analyst price targets and some intrinsic value estimates, is Hinge Health undervalued today, or is the market already pricing in future growth?

Most Popular Narrative: 9% Undervalued

Hinge Health’s most followed narrative puts fair value at $64.29, above the last close at $58.48, framing the recent share price move against a higher long term anchor.

Expansion of integrated digital and in person offerings through HingeSelect and broader provider network build out positions the company to pursue a larger share of MSK and adjacent care pathways, potentially increasing lives under contract and long term revenue per client.

Curious what supports that higher fair value. The narrative leans on faster revenue growth, a sharp margin swing into profit and a rich future earnings multiple.

Result: Fair Value of $64.29 (UNDERVALUED)

However, this hinges on employers and health plans sticking with digital MSK tools, and on AI driven automation avoiding regulatory or data privacy setbacks that could squeeze margins.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Another View: Rich Sales Multiple Keeps Expectations High

While the narrative and intrinsic estimates point to Hinge Health trading below fair value, the current P/S of 7x tells a different story. It is higher than both the US Healthcare industry average of 1.2x and the estimated fair ratio of 6.7x. This leaves less room for error if growth or margins fall short.

To see how this stacks up against peers and what the fair ratio suggests the market could move toward, take a closer look at our valuation breakdown with See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

If this mix of optimism and caution has you on the fence, take a moment to review the details yourself and form a clear stance with 4 key rewards.

Looking for more investment ideas?

If Hinge Health has sharpened your focus, do not stop here. Broaden your watchlist with focused stock ideas while the market keeps moving without you.

• Hunt for potential bargains with strong fundamentals by scanning 46 high quality undervalued stocks tailored to highlight quality alongside pricing.
• Build a steadier core for your portfolio by reviewing income focused opportunities in 11 dividend fortresses offering higher yields.
• Lean toward resilience by checking stocks flagged in 63 resilient stocks with low risk scores where balance sheets and risk scores aim to keep surprises in check.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.